Skip to main content
  • Saved

made a Post

Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets: Lipid-lowering combination therapy

Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets: Lipid-lowering combination therapy

Source :

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305062/

Lipid-lowering combination therapy Keywords: Lipid-lowering combination therapy, Statins, Ezetimibe, PCSK9 inhibitors, Cardiovascular prevention In the last 35 years, many randomized controlled trials have tested the impact of lipid-lowering drugs on cardiovascular disease (CVD) risk. In the pre-statin era, the Lipid Research Clinics trial [ 1] showed a benefit associated with a rather moderate cholesterol reduction induced by cholestyramine.